{"id":23284,"date":"2025-06-17T05:00:00","date_gmt":"2025-06-17T10:00:00","guid":{"rendered":"https:\/\/tiro.expert\/?p=23284"},"modified":"2025-06-17T05:00:00","modified_gmt":"2025-06-17T10:00:00","slug":"unresectable-vs-resectable-thyroid-cancer-pt-1","status":"publish","type":"post","link":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/","title":{"rendered":"C\u00e1ncer de tiroides irresecable vs. resecable (Pt. 1)"},"content":{"rendered":"<p><iframe loading=\"lazy\" allowtransparency=\"true\" height=\"150\" width=\"100%\" style=\"border: none;\" scrolling=\"no\" data-name=\"pb-iframe-player\" src=\"https:\/\/www.podbean.com\/player-v2\/?share=1&#038;download=0&#038;rtl=0&#038;fonts=Arial&#038;skin=654771&#038;btn-skin=654771&#038;multiple_size=315&#038;square_size=300&#038;order=episodic&#038;filter=all&#038;limit=10&#038;season=all&#038;tag=all&#038;font-color=auto&#038;logo_link=podcast_page&#038;i=ixvhr-18ae77f-pb\"><\/iframe><\/p>\n<p><span style=\"font-weight:400;\">\u00bfQu\u00e9 hace que un tumor de tiroides sea realmente irresecable? En este episodio, la Dra. Dana Hartl habla con el Dr. Mark Zafereo sobre c\u00f3mo las pruebas moleculares y las terapias neoadyuvantes dirigidas est\u00e1n redefiniendo la elegibilidad quir\u00fargica de los pacientes con c\u00e1ncer anapl\u00e1sico de tiroides. Escuche c\u00f3mo exploran el papel cambiante de los inhibidores de BRAF\/MEK, las estrategias de diagn\u00f3stico por imagen y la toma de decisiones en el mundo real en casos complejos.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>\u00bfQu\u00e9 hace que un tumor de tiroides sea realmente irresecable? En este episodio, la Dra. Dana Hartl habla con el Dr. Mark Zafereo sobre c\u00f3mo las pruebas moleculares y las terapias neoadyuvantes dirigidas est\u00e1n redefiniendo la elegibilidad quir\u00fargica de los pacientes con c\u00e1ncer anapl\u00e1sico de tiroides. Escuche c\u00f3mo exploran el papel cambiante de los inhibidores de BRAF\/MEK, las estrategias de diagn\u00f3stico por imagen y la toma de decisiones en el mundo real en casos complejos.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-23284","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tw-post-no-content"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO Pro 5.0.5.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"What makes a thyroid tumor truly unresectable? In this episode, Dr. Dana Hartl speaks with Dr. Mark Zafereo about how molecular testing and targeted neoadjuvant therapies are redefining surgical eligibility for patients with anaplastic thyroid cancer. Listen in as they explore the evolving role of BRAF\/MEK inhibitors, imaging strategies, and real-world decision-making in complex cases.\" \/>\n\t<meta name=\"robots\" content=\"nosnippet, max-image-preview:large, max-video-preview:-1\" \/>\n\t<meta name=\"author\" content=\"THANC Foundation\"\/>\n\t<meta name=\"google-site-verification\" content=\"dgn_KNbWOqdQMThGOuzuLswqwKwBsjcS82PzbL7RTr4\" \/>\n\t<meta name=\"msvalidate.01\" content=\"665B47E811A7F57E1C97131210D3FD3A\" \/>\n\t<meta name=\"keywords\" content=\"uncategorized\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 5.0.5.1\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/2025\\\/06\\\/unresectable-vs-resectable-thyroid-cancer-pt-1\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tiro.expert\\\/es\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/category\\\/uncategorized\\\/#listItem\",\"name\":\"Uncategorized\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/category\\\/uncategorized\\\/#listItem\",\"position\":2,\"name\":\"Uncategorized\",\"item\":\"https:\\\/\\\/tiro.expert\\\/es\\\/category\\\/uncategorized\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/2025\\\/06\\\/unresectable-vs-resectable-thyroid-cancer-pt-1\\\/#listItem\",\"name\":\"Unresectable vs. Resectable Thyroid Cancer (Pt. 1)\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/2025\\\/06\\\/unresectable-vs-resectable-thyroid-cancer-pt-1\\\/#listItem\",\"position\":3,\"name\":\"Unresectable vs. Resectable Thyroid Cancer (Pt. 1)\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/category\\\/uncategorized\\\/#listItem\",\"name\":\"Uncategorized\"}}]},{\"@type\":\"Course\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/2025\\\/06\\\/unresectable-vs-resectable-thyroid-cancer-pt-1\\\/#course\",\"name\":\"Unresectable vs. Resectable Thyroid Cancer (Pt. 1)\",\"description\":\"What makes a thyroid tumor truly unresectable? In this episode, Dr. Dana Hartl speaks with Dr. Mark Zafereo about how molecular testing and targeted neoadjuvant therapies are redefining surgical eligibility for patients with anaplastic thyroid cancer. Listen in as they explore the evolving role of BRAF\\\/MEK inhibitors, imaging strategies, and real-world decision-making in complex cases.\",\"datePublished\":\"2025-06-17\",\"provider\":{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/#organization\"}},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/#organization\",\"name\":\"Thyroid Int'l Recommendations Online (TIRO)\",\"description\":\"Thyroid Int'l Recommendations Online\",\"url\":\"https:\\\/\\\/tiro.expert\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/tiro.expert\\\/wp-content\\\/uploads\\\/2021\\\/01\\\/TIRO-secondary-logo-siteID.png\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/2025\\\/06\\\/unresectable-vs-resectable-thyroid-cancer-pt-1\\\/#organizationLogo\",\"width\":847,\"height\":278,\"caption\":\"TIRO Thyroid International Recommendations Online secondary logo\"},\"image\":{\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/2025\\\/06\\\/unresectable-vs-resectable-thyroid-cancer-pt-1\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/thancfoundation\",\"https:\\\/\\\/twitter.com\\\/thancfoundation\",\"https:\\\/\\\/instagram.com\\\/thancfoundation\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC4Y_bz_8BmgUU96NWdpBkdw\\\/feed\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/author\\\/hncg2-admin\\\/#author\",\"url\":\"https:\\\/\\\/tiro.expert\\\/es\\\/author\\\/hncg2-admin\\\/\",\"name\":\"THANC Foundation\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/2025\\\/06\\\/unresectable-vs-resectable-thyroid-cancer-pt-1\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a7a0d3017fb58318083321994a81ffc0be78bc1c2c039df03c936c365bab39fb?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"THANC Foundation\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/2025\\\/06\\\/unresectable-vs-resectable-thyroid-cancer-pt-1\\\/#webpage\",\"url\":\"https:\\\/\\\/tiro.expert\\\/es\\\/2025\\\/06\\\/unresectable-vs-resectable-thyroid-cancer-pt-1\\\/\",\"name\":\"Unresectable vs. Resectable Thyroid Cancer (Pt. 1) \\u2023 TIRO\",\"description\":\"What makes a thyroid tumor truly unresectable? In this episode, Dr. Dana Hartl speaks with Dr. Mark Zafereo about how molecular testing and targeted neoadjuvant therapies are redefining surgical eligibility for patients with anaplastic thyroid cancer. Listen in as they explore the evolving role of BRAF\\\/MEK inhibitors, imaging strategies, and real-world decision-making in complex cases.\",\"inLanguage\":\"es-MX\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/2025\\\/06\\\/unresectable-vs-resectable-thyroid-cancer-pt-1\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/author\\\/hncg2-admin\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/author\\\/hncg2-admin\\\/#author\"},\"datePublished\":\"2025-06-17T05:00:00-05:00\",\"dateModified\":\"2025-06-17T05:00:00-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/tiro.expert\\\/es\\\/\",\"name\":\"TIRO\",\"description\":\"Thyroid Int'l Recommendations Online\",\"inLanguage\":\"es-MX\",\"publisher\":{\"@id\":\"https:\\\/\\\/tiro.expert\\\/es\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO Pro -->\r\n\t\t<title>Unresectable vs. Resectable Thyroid Cancer (Pt. 1) \u2023 TIRO<\/title>\n\n","aioseo_head_json":{"title":"C\u00e1ncer de tiroides irresecable frente a resecable (Pt. 1) \u2023 TIRO","description":"\u00bfQu\u00e9 hace que un tumor de tiroides sea realmente irresecable? En este episodio, la Dra. Dana Hartl habla con el Dr. Mark Zafereo sobre c\u00f3mo las pruebas moleculares y las terapias neoadyuvantes dirigidas est\u00e1n redefiniendo la elegibilidad quir\u00fargica de los pacientes con c\u00e1ncer anapl\u00e1sico de tiroides. Escuche c\u00f3mo exploran el papel cambiante de los inhibidores de BRAF\/MEK, las estrategias de diagn\u00f3stico por imagen y la toma de decisiones en el mundo real en casos complejos.","canonical_url":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/","robots":"nosnippet, max-image-preview:large, max-video-preview:-1","keywords":"uncategorized","webmasterTools":{"google-site-verification":"dgn_KNbWOqdQMThGOuzuLswqwKwBsjcS82PzbL7RTr4","msvalidate.01":"665B47E811A7F57E1C97131210D3FD3A","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/tiro.expert\/es\/#listItem","position":1,"name":"Home","item":"https:\/\/tiro.expert\/es\/","nextItem":{"@type":"ListItem","@id":"https:\/\/tiro.expert\/es\/category\/uncategorized\/#listItem","name":"Uncategorized"}},{"@type":"ListItem","@id":"https:\/\/tiro.expert\/es\/category\/uncategorized\/#listItem","position":2,"name":"Uncategorized","item":"https:\/\/tiro.expert\/es\/category\/uncategorized\/","nextItem":{"@type":"ListItem","@id":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/#listItem","name":"Unresectable vs. Resectable Thyroid Cancer (Pt. 1)"},"previousItem":{"@type":"ListItem","@id":"https:\/\/tiro.expert\/es\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/#listItem","position":3,"name":"Unresectable vs. Resectable Thyroid Cancer (Pt. 1)","previousItem":{"@type":"ListItem","@id":"https:\/\/tiro.expert\/es\/category\/uncategorized\/#listItem","name":"Uncategorized"}}]},{"@type":"Course","@id":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/#course","name":"Unresectable vs. Resectable Thyroid Cancer (Pt. 1)","description":"What makes a thyroid tumor truly unresectable? In this episode, Dr. Dana Hartl speaks with Dr. Mark Zafereo about how molecular testing and targeted neoadjuvant therapies are redefining surgical eligibility for patients with anaplastic thyroid cancer. Listen in as they explore the evolving role of BRAF\/MEK inhibitors, imaging strategies, and real-world decision-making in complex cases.","datePublished":"2025-06-17","provider":{"@type":"Organization","@id":"https:\/\/tiro.expert\/es\/#organization"}},{"@type":"Organization","@id":"https:\/\/tiro.expert\/es\/#organization","name":"Thyroid Int'l Recommendations Online (TIRO)","description":"Thyroid Int'l Recommendations Online","url":"https:\/\/tiro.expert\/es\/","logo":{"@type":"ImageObject","url":"https:\/\/tiro.expert\/wp-content\/uploads\/2021\/01\/TIRO-secondary-logo-siteID.png","@id":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/#organizationLogo","width":847,"height":278,"caption":"TIRO Thyroid International Recommendations Online secondary logo"},"image":{"@id":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/thancfoundation","https:\/\/twitter.com\/thancfoundation","https:\/\/instagram.com\/thancfoundation\/","https:\/\/www.youtube.com\/channel\/UC4Y_bz_8BmgUU96NWdpBkdw\/feed"]},{"@type":"Person","@id":"https:\/\/tiro.expert\/es\/author\/hncg2-admin\/#author","url":"https:\/\/tiro.expert\/es\/author\/hncg2-admin\/","name":"THANC Foundation","image":{"@type":"ImageObject","@id":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/a7a0d3017fb58318083321994a81ffc0be78bc1c2c039df03c936c365bab39fb?s=96&d=mm&r=g","width":96,"height":96,"caption":"THANC Foundation"}},{"@type":"WebPage","@id":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/#webpage","url":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/","name":"Unresectable vs. Resectable Thyroid Cancer (Pt. 1) \u2023 TIRO","description":"What makes a thyroid tumor truly unresectable? In this episode, Dr. Dana Hartl speaks with Dr. Mark Zafereo about how molecular testing and targeted neoadjuvant therapies are redefining surgical eligibility for patients with anaplastic thyroid cancer. Listen in as they explore the evolving role of BRAF\/MEK inhibitors, imaging strategies, and real-world decision-making in complex cases.","inLanguage":"es-MX","isPartOf":{"@id":"https:\/\/tiro.expert\/es\/#website"},"breadcrumb":{"@id":"https:\/\/tiro.expert\/es\/2025\/06\/unresectable-vs-resectable-thyroid-cancer-pt-1\/#breadcrumblist"},"author":{"@id":"https:\/\/tiro.expert\/es\/author\/hncg2-admin\/#author"},"creator":{"@id":"https:\/\/tiro.expert\/es\/author\/hncg2-admin\/#author"},"datePublished":"2025-06-17T05:00:00-05:00","dateModified":"2025-06-17T05:00:00-05:00"},{"@type":"WebSite","@id":"https:\/\/tiro.expert\/es\/#website","url":"https:\/\/tiro.expert\/es\/","name":"TIRO","description":"Thyroid Int'l Recommendations Online","inLanguage":"es-MX","publisher":{"@id":"https:\/\/tiro.expert\/es\/#organization"}}]}},"aioseo_meta_data":{"post_id":"23284","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"Course","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"seo_analyzer_scan_date":"2026-11-09 02:48:57","breadcrumb_settings":null,"limit_modified_date":false,"open_ai":null,"ai":null,"created":"2025-06-17 16:57:27","updated":"2026-11-09 02:48:57","focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"THANC Foundation","author_link":"https:\/\/tiro.expert\/es\/author\/hncg2-admin\/"},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false,"gb-block-post-grid-landscape":false,"gb-block-post-grid-square":false,"post-thumbnail":false,"twentytwenty-fullscreen":false},"uagb_author_info":{"display_name":"THANC Foundation","author_link":"https:\/\/tiro.expert\/es\/author\/hncg2-admin\/"},"uagb_comment_info":0,"uagb_excerpt":"What makes a thyroid tumor truly unresectable? In this episode, Dr. Dana Hartl speaks with Dr. Mark Zafereo about how molecular testing and targeted neoadjuvant therapies are redefining surgical eligibility for patients with anaplastic thyroid cancer. Listen in as they explore the evolving role of BRAF\/MEK inhibitors, imaging strategies, and real-world decision-making in complex cases.","publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/tiro.expert\/es\/wp-json\/wp\/v2\/posts\/23284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tiro.expert\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tiro.expert\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tiro.expert\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tiro.expert\/es\/wp-json\/wp\/v2\/comments?post=23284"}],"version-history":[{"count":0,"href":"https:\/\/tiro.expert\/es\/wp-json\/wp\/v2\/posts\/23284\/revisions"}],"wp:attachment":[{"href":"https:\/\/tiro.expert\/es\/wp-json\/wp\/v2\/media?parent=23284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tiro.expert\/es\/wp-json\/wp\/v2\/categories?post=23284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tiro.expert\/es\/wp-json\/wp\/v2\/tags?post=23284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}